Back to Search
Start Over
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
- Source :
-
Ugeskrift for laeger [Ugeskr Laeger] 2009 Jan 05; Vol. 171 (1-2), pp. 50-2. - Publication Year :
- 2009
-
Abstract
- Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON increases with the duration of bisphosphonate therapy and with the potency of the used bisphosphonate. BON usually develops after tooth extraction or other oral surgery, and has proven difficult to treat. Optimal dental hygiene should be ensured prior to treatment initiation where possible, and once bisphosphonate treatment is instituted, oral surgery should be avoided if possible.
- Subjects :
- Humans
Jaw pathology
Oral Hygiene
Osteonecrosis prevention & control
Pamidronate
Risk Factors
Zoledronic Acid
Bone Density Conservation Agents adverse effects
Diphosphonates adverse effects
Imidazoles adverse effects
Jaw drug effects
Multiple Myeloma drug therapy
Osteonecrosis chemically induced
Subjects
Details
- Language :
- Danish
- ISSN :
- 1603-6824
- Volume :
- 171
- Issue :
- 1-2
- Database :
- MEDLINE
- Journal :
- Ugeskrift for laeger
- Publication Type :
- Academic Journal
- Accession number :
- 19128568